It is "not yet" necessary to adapt the Pfizer vaccine to the variants, said the boss of BioNTech, the laboratory which developed the messenger RNA vaccine jointly with the American firm.
Faced with the surge in contamination due to the Delta variant, the question of injecting a third dose of vaccine in order to be better immunized arises.
As is the possibility for laboratories to revise the formulation of anti-Covid vaccines specifically to target the variants in circulation.
>> More information to come on www.20minutes.fr
World
Coronavirus: Full US green light for Pfizer vaccine expected to arrive in September
Health
Coronavirus: Moderna ensures that its vaccine is effective for at least six months
Health